Cite
HARVARD Citation
Antill, Y. et al. (2021). Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. Journal for immunotherapy of cancer. 9 (6), p. . [Online].